|
Post by admin on Sept 11, 2005 19:36:40 GMT -5
University of Texas MD Anderson Cancer Center Pediatric Division NewsletterPhase II protocols using DX-8951f(Exatecan) for the treatment of rhabdomyosarcoma, Ewing's sarcoma or desmoplastic small round cell tumor are currently open. DX-8951f is an inhibitor of topoisomerase 1. More potent than either topotecan or irinotecan, phase I trials had responses in patients who previously received other topoisomerase 1 inhibitors. The diarrhea often seen with irinotecan has not been a problem with DX-8951f. The drug is give IV over 30 minutes daily for five days in 21 day cycles. For more infomation contact Dr Cynthia Herzog 713-792-5055.
|
|